Columbus Circle Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Columbus Circle Investors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-63,398	Closed	-$1.11M	–	301
2016 Q1	$1.11M	Buy	63,398 +2,103	+3%	+$42.8K	0.01%	238
2015 Q4	$2.09M	Buy	61,295 +35,734	+140%	+$1.24M	0.02%	241
2015 Q3	$761K	Buy	25,561 +4,338	+20%	+$132K	0.01%	256
2015 Q2	$679K	Buy	21,223 +799	+4%	+$20.5K	﹤0.01%	258
2015 Q1	$423K	Sell	20,424 -17,594	-46%	-$304K	﹤0.01%	277
2014 Q4	$644K	Sell	38,018 -17,723	-32%	-$310K	﹤0.01%	272
2014 Q3	$1.08M	Buy	+55,741	New	+$1.45M	0.01%	234

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NHG

NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Columbus Circle Investors's RVNC Position: Q2 2016 in Review

Columbus Circle Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2016, closing a stake of 63,398 shares — an estimated $1.11M sold.

Columbus Circle Investors first reported a position in RVNC in Q3 2014 and held it in 7 quarters. The position peaked at $2.09M in Q4 2015. 82 funds tracked by Wall St. Rank hold RVNC as of Q2 2016.

Columbus Circle Investors reported no remaining Revance Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Columbus Circle Investors sold 63,398 Revance Therapeutics, Inc. shares in Q2 2016, an estimated $1.11M.
Columbus Circle Investors first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 7 quarters.
Columbus Circle Investors's Revance Therapeutics, Inc. position peaked at $2.09M in Q4 2015.
82 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2016.

Based on Columbus Circle Investors's 13F filing for Q2 2016, filed 2 Aug 2016.